JP2000198718A - External preparation for promoting blood circulation - Google Patents
External preparation for promoting blood circulationInfo
- Publication number
- JP2000198718A JP2000198718A JP11298559A JP29855999A JP2000198718A JP 2000198718 A JP2000198718 A JP 2000198718A JP 11298559 A JP11298559 A JP 11298559A JP 29855999 A JP29855999 A JP 29855999A JP 2000198718 A JP2000198718 A JP 2000198718A
- Authority
- JP
- Japan
- Prior art keywords
- hair
- external preparation
- adenosine
- blood circulation
- phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 54
- 230000017531 blood circulation Effects 0.000 title claims abstract description 46
- 230000001737 promoting effect Effects 0.000 title claims abstract description 37
- 210000004209 hair Anatomy 0.000 claims abstract description 80
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims abstract description 43
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims abstract description 22
- 229960005305 adenosine Drugs 0.000 claims abstract description 22
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims abstract description 22
- 229950006790 adenosine phosphate Drugs 0.000 claims abstract description 21
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000036541 health Effects 0.000 abstract description 4
- 230000001256 tonic effect Effects 0.000 abstract description 4
- 230000003796 beauty Effects 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 230000002500 effect on skin Effects 0.000 abstract description 2
- 210000003205 muscle Anatomy 0.000 abstract description 2
- 239000007921 spray Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 54
- 230000003779 hair growth Effects 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- 239000012071 phase Substances 0.000 description 31
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 24
- 238000012360 testing method Methods 0.000 description 23
- 235000019441 ethanol Nutrition 0.000 description 19
- 210000003491 skin Anatomy 0.000 description 18
- 239000000203 mixture Substances 0.000 description 16
- 239000007788 liquid Substances 0.000 description 15
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 description 14
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 13
- 239000004359 castor oil Substances 0.000 description 13
- 235000019438 castor oil Nutrition 0.000 description 13
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- 201000004384 Alopecia Diseases 0.000 description 11
- 230000009471 action Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 208000024963 hair loss Diseases 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 230000003676 hair loss Effects 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 8
- 230000003797 telogen phase Effects 0.000 description 8
- -1 adenosine compound Chemical class 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 230000003405 preventing effect Effects 0.000 description 6
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 5
- 238000013329 compounding Methods 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 5
- 210000004761 scalp Anatomy 0.000 description 5
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 210000003780 hair follicle Anatomy 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 238000005342 ion exchange Methods 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229940032094 squalane Drugs 0.000 description 4
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 150000003838 adenosines Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 3
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000003660 hair regeneration Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- UTTVXKGNTWZECK-UHFFFAOYSA-N n,n-dimethyloctadecan-1-amine oxide Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)[O-] UTTVXKGNTWZECK-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 150000003016 phosphoric acids Chemical class 0.000 description 2
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000003658 preventing hair loss Effects 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 2
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 2
- 229940075562 sodium phosphate dihydrate Drugs 0.000 description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
- WBIQQQGBSDOWNP-UHFFFAOYSA-N 2-dodecylbenzenesulfonic acid Chemical compound CCCCCCCCCCCCC1=CC=CC=C1S(O)(=O)=O WBIQQQGBSDOWNP-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VQAWRQZAAIQXHM-UHFFFAOYSA-N Cepharanthine Natural products O1C(C=C2)=CC=C2CC(C=23)N(C)CCC3=CC=3OCOC=3C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C(O)C1=C2 VQAWRQZAAIQXHM-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- KCFRUUYAXCDZNZ-UHFFFAOYSA-N N-dodecanoyltaurine Chemical compound CCCCCCCCCCCC(=O)NCCS(O)(=O)=O KCFRUUYAXCDZNZ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical compound NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N Taurine Natural products NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical class CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010045569 atelocollagen Proteins 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- JFIOVJDNOJYLKP-UHFFFAOYSA-N bithionol Chemical compound OC1=C(Cl)C=C(Cl)C=C1SC1=CC(Cl)=CC(Cl)=C1O JFIOVJDNOJYLKP-UHFFFAOYSA-N 0.000 description 1
- 229960002326 bithionol Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- RZMKWKZIJJNSLQ-UHFFFAOYSA-M carpronium chloride Chemical compound [Cl-].COC(=O)CCC[N+](C)(C)C RZMKWKZIJJNSLQ-UHFFFAOYSA-M 0.000 description 1
- 229950003631 carpronium chloride Drugs 0.000 description 1
- YVPXVXANRNDGTA-WDYNHAJCSA-N cepharanthine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-WDYNHAJCSA-N 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- OYERHOIFBRDTSU-IDIVVRGQSA-L dipotassium;[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound [K+].[K+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])([O-])=O)[C@@H](O)[C@H]1O OYERHOIFBRDTSU-IDIVVRGQSA-L 0.000 description 1
- HDDUZEKWRALMDG-MSQVLRTGSA-L disodium;[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate;hydrate Chemical compound O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])([O-])=O)[C@@H](O)[C@H]1O HDDUZEKWRALMDG-MSQVLRTGSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- YRIUSKIDOIARQF-UHFFFAOYSA-N dodecyl benzenesulfonate Chemical compound CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 YRIUSKIDOIARQF-UHFFFAOYSA-N 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- 229940071161 dodecylbenzenesulfonate Drugs 0.000 description 1
- 229940060296 dodecylbenzenesulfonic acid Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 229960004068 hexachlorophene Drugs 0.000 description 1
- OIKBVOIOVNEVJR-UHFFFAOYSA-N hexadecyl 6-methylheptanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCC(C)C OIKBVOIOVNEVJR-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229940070891 pyridium Drugs 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- JHJUUEHSAZXEEO-UHFFFAOYSA-M sodium;4-dodecylbenzenesulfonate Chemical compound [Na+].CCCCCCCCCCCCC1=CC=C(S([O-])(=O)=O)C=C1 JHJUUEHSAZXEEO-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960001325 triclocarban Drugs 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、皮膚外用剤(養毛
料を含む)に関する技術分野の発明である。より具体的
には、本発明は、外用することにより、使用箇所近傍の
血流を促進させることが可能な血行促進外用剤に関する
発明である。この血行促進外用剤は、その優れた血行促
進作用を、例えば、脱毛防止作用,発毛促進作用等の養
毛作用として発揮し得る養毛料等として用いることが好
適である。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an external preparation for skin (including a hair nourishing agent) in the technical field. More specifically, the present invention relates to a blood circulation-promoting external preparation capable of promoting blood flow near a point of use by external use. This external preparation for promoting blood circulation is preferably used as a hair restorer or the like capable of exhibiting its excellent blood circulation promoting action as, for example, a hair restoration action such as a hair loss preventing action and a hair growth promoting action.
【0002】[0002]
【従来の技術】皮膚近傍の血行促進を図ることは、様々
な側面における重要事項である。皮膚近傍における血行
の悪化は、肩こり、頭痛等の原因となり、健康上好まし
くないことはよく知られていることである。また、肌の
くすみ等を惹き起こす等、美容上も、血行が悪くなるこ
とは好ましくない。さらに、頭皮における血行不良は、
脱毛の大きな原因になることが知られている。2. Description of the Related Art Promoting blood circulation near the skin is an important matter in various aspects. It is well known that deterioration of blood circulation near the skin causes stiff shoulders, headaches, etc., and is not preferable for health. In addition, it is not preferable that blood circulation deteriorates from the viewpoint of beauty, such as causing dull skin. In addition, poor circulation in the scalp
It is known to be a major cause of hair loss.
【0003】血行は、様々な原因で障害を受けることが
知られているが、健常人においてもしばしば認められる
原因として、寝不足やストレスが挙げられる。これらの
原因に晒される機会は、現代社会においては、ますます
増加している。すなわち、現代社会の生活時間帯は、一
昔前と比べて深夜にズレ込む傾向が強くなり、慢性的な
寝不足が増加していることは明らかである。また、現代
社会は、ストレス社会ともいわれ、様々なストレス要因
が増加している。[0003] Blood circulation is known to be affected by various causes, but lack of sleep and stress are also common causes in healthy people. Opportunities to be exposed to these causes are increasing in modern society. In other words, it is clear that the tendency of living hours in modern society to shift to late at night is stronger than in the past, and that chronic sleep shortage is increasing. In addition, the modern society is also called a stress society, and various stress factors are increasing.
【0004】[0004]
【発明が解決しようとする課題】上述したような、皮膚
近傍の血行の悪化は、例えば、湯治等により回復させる
ことが可能であるが、これを行うには、十分な時間や相
当の費用を要する。よって、手軽に血行を促進すること
が可能な手段を提供することは、美容上、健康上から非
常に好ましいことである。The deterioration of blood circulation near the skin as described above can be recovered by, for example, spa treatment, but this requires a sufficient amount of time and considerable expense. It costs. Therefore, providing a means capable of easily promoting blood circulation is very preferable from a cosmetic and health point of view.
【0005】本発明が解決すべき課題は、外用すること
により、皮膚近傍の血行を促進させることが可能な成分
を見出し、これを有効成分とする皮膚外用剤、すなわ
ち、血行促進外用剤を提供することにある。The problem to be solved by the present invention is to find a component capable of promoting blood circulation near the skin by external use, and to provide a skin external preparation containing the active ingredient as an active ingredient, that is, a blood circulation promoting external preparation. Is to do.
【0006】[0006]
【課題を解決するための手段】本発明者は、上記の課題
を鑑み、様々な成分について血行促進効果についての検
討を行った結果、アデノシン、アデノシン5’−リン
酸、及び、アデノシン5’−リン酸の塩に優れた血行促
進効果が認められ、この血行促進効果と相まって、優れ
た脱毛防止作用や発毛促進作用等の養毛作用が認められ
ることを見出し、これらの成分を皮膚外用剤の有効成分
として用いることにより、所望する血行促進外用剤を提
供することが可能であることを見出した。Means for Solving the Problems In view of the above-mentioned problems, the present inventor examined the effects of promoting blood circulation on various components, and as a result, found that adenosine, adenosine 5'-phosphate, and adenosine 5'-. Phosphoric acid salt has an excellent blood circulation promoting effect, and in combination with this blood circulation promoting effect, it has been found that it has excellent hair growth preventing effects such as hair loss preventing effect and hair growth promoting effect. It has been found that by using the compound as an active ingredient, it is possible to provide a desired external preparation for promoting blood circulation.
【0007】すなわち、本発明は、アデノシン、アデノ
シン5’−リン酸及び/又はアデノシン5’−リン酸の
塩を有効成分として含有する血行促進外用剤(以下、本
発明外用剤ともいう)を提供する発明である。That is, the present invention provides an external preparation for promoting blood circulation containing adenosine, adenosine 5'-phosphate and / or adenosine 5'-phosphate as an active ingredient (hereinafter also referred to as the external preparation of the present invention). It is an invention to do.
【0008】なお、本発明外用剤の剤の形態は、外皮
(頭皮頭髪を含む)に適用可能な形態であれば、特に限
定されず、化粧品、医薬品、医薬部外品等の薬事法上の
区別に拘束されるものではない。[0008] The form of the external preparation of the present invention is not particularly limited as long as it can be applied to the outer skin (including the scalp and hair). It is not bound by distinction.
【0009】本発明外用剤の典型的な剤の形態として、
養毛料が挙げられる(以下、本発明養毛料ともいう)。
本発明において「養毛」とは、脱毛防止作用,発毛促進
作用等を包含する概念で使用される。また、本発明養毛
料は、頭髪の育毛用薬用化粧料等を包含する皮膚外用組
成物として使用できる。The typical form of the external preparation of the present invention is as follows:
Hair restoration (hereinafter also referred to as the hair restoration of the present invention).
In the present invention, “hair growth” is used in a concept including a hair loss preventing action, a hair growth promoting action, and the like. In addition, the hair restorer of the present invention can be used as a composition for external use on the skin including a cosmeceutical for hair growth of head hair and the like.
【0010】[0010]
【発明の実施の形態】以下、本発明の実施の形態につい
て説明する。本発明外用剤の有効成分 本発明外用剤の有効成分は、上述したように、アデノシ
ン、アデノシン5’−リン酸及び/又はアデノシン5’
−リン酸の塩(以下、アデノシン類ともいう)である。Embodiments of the present invention will be described below. Active ingredient of the external preparation of the present invention As described above, the active ingredient of the external preparation of the present invention comprises adenosine, adenosine 5′-phosphate and / or adenosine 5 ′.
-Phosphoric acid salts (hereinafter also referred to as adenosines).
【0011】アデノシンは、リボヌクレオシドの一つで
塩基部分にプリン誘導体であるアデニンを含むものであ
る。アデノシン5’−リン酸は、5’−アデニル酸とも
呼ばれ、アデノシンのリボースの5’位のヒドロキシル
基にリン酸が1分子結合したヌクレオチドである。Adenosine is one of ribonucleosides and contains adenine which is a purine derivative in the base portion. Adenosine 5'-phosphate is also called 5'-adenylic acid, and is a nucleotide in which one molecule of phosphate binds to the 5'-hydroxyl group of ribose of adenosine.
【0012】また、アデノシン5’−リン酸の塩におい
て、塩を形成する対イオンとしては、酸と対イオンを形
成する物質であればいずれの物質でもよく、例えば、ナ
トリウム,カリウム,カルシウム等を挙げることができ
る。また、アデノシン5’−リン酸の塩としては、その
水和物を使用することもできる。In the salt of adenosine 5'-phosphate, the counter ion forming the salt may be any substance as long as it forms a counter ion with an acid. For example, sodium, potassium, calcium and the like may be used. Can be mentioned. As the salt of adenosine 5′-phosphate, a hydrate thereof can also be used.
【0013】本発明外用剤において、アデノシン、アデ
ノシン5’−リン酸及びアデノシン5’−リン酸の塩
は、試薬として市販されているものを使用することもで
きる。本発明外用剤におけるアデノシン類の配合量は、
剤の具体的な形態や他の配合成分との兼ね合いに応じて
適宜選択するべきものであり、特に限定されるものでは
ない。In the external preparation of the present invention, as adenosine, adenosine 5'-phosphate and salts of adenosine 5'-phosphate, commercially available reagents can be used. The amount of adenosine in the external preparation of the present invention is,
It should be appropriately selected according to the specific form of the agent and the balance with other components, and is not particularly limited.
【0014】例えば、本発明外用剤が、養毛料である場
合には、一般に、養毛料全量中、0. 01〜20.0重
量%であり、好ましくは0. 1〜10.0重量%であ
る。この配合量が、養毛料全量中0.01重量%未満で
は、上記有効成分による養毛効果が十分に発揮されず好
ましくなく、同20.0重量%を超えると、製剤上支障
をきたす傾向が顕著となり好ましくない。For example, when the external preparation of the present invention is a hair restorer, it is generally used in an amount of 0.01 to 20.0% by weight, preferably 0.1 to 10.0% by weight, based on the total amount of the hair restorer. is there. If the amount is less than 0.01% by weight of the total amount of the hair restorer, the active ingredient does not sufficiently exert the hair-growth effect, which is not preferable. If the amount exceeds 20.0% by weight, the formulation tends to be hindered. It becomes remarkable and is not preferable.
【0015】このようにして、皮膚近傍(皮膚内ないし
経皮吸収により到達する筋肉内)の血行を促進し、美容
と健康に資する本発明外用剤が提供される。本発明外用剤の具体的な形態 本発明外用剤は、アデノシン類を有効成分として含有し
て、皮膚近傍における血行促進作用を発揮する皮膚外用
剤である。Thus, the external preparation of the present invention which promotes blood circulation near the skin (in the skin or in the muscle reached by transdermal absorption) and contributes to beauty and health is provided. Specific form of the external preparation of the present invention The external preparation of the present invention is a skin external preparation that contains an adenosine compound as an active ingredient and exerts a blood circulation promoting action near the skin.
【0016】本発明外用剤には、具体的な形態に応じた
公知の成分を配合することが可能である。すなわち、皮
膚外用剤において、通常用いられ得る成分を、本発明の
所期の効果を損なわない範囲で配合することができる。
例えば、油分(固形パラフィン,流動パラフィン,シリ
コーン油,スクワラン,モノオレイン酸グリセリル,オ
リーブ油,高級アルコール,高級脂肪酸,イソプロピル
ミリステート等)、保湿剤(多価アルコール,例えばグ
リセリン,プロピレングリコール,ヒアルロン酸,マル
チトール,アテロコラーゲン,乳酸ナトリウム等)、増
粘剤(マルメロ粘質物,カルボキシビニルポリマー,キ
サンタンガム等)、抗菌剤、薬剤、酸化防止剤、紫外線
防御剤、香料、色剤、界面活性剤、水、エタノール等を
配合することができる。The external preparation of the present invention can contain known components according to the specific form. That is, in a skin external preparation, components that can be generally used can be blended within a range that does not impair the intended effect of the present invention.
For example, oil (solid paraffin, liquid paraffin, silicone oil, squalane, glyceryl monooleate, olive oil, higher alcohol, higher fatty acid, isopropyl myristate, etc.), humectant (polyhydric alcohol such as glycerin, propylene glycol, hyaluronic acid, Maltitol, atelocollagen, sodium lactate, etc.), thickeners (quince, carboxyvinyl polymer, xanthan gum, etc.), antibacterial agents, drugs, antioxidants, UV protection agents, fragrances, coloring agents, surfactants, water, Ethanol and the like can be blended.
【0017】本発明外用剤の剤型は特に限定されず、例
えば水溶液系、可溶化系、乳化系、粉末分散系、水−油
2層系、水−油−粉末3層系等、外用組成物全般にわた
って本発明を適用することが可能である。The dosage form of the external preparation of the present invention is not particularly limited. For example, an external composition such as an aqueous solution, a solubilizing system, an emulsifying system, a powder dispersing system, a water-oil two-layer system, a water-oil-powder three-layer system, etc. The present invention can be applied to all products.
【0018】本発明外用剤は、皮膚に直接に塗布または
散布する経皮投与により投与することができる。また、
その投与量は、外用剤の具体的態様、使用者の年齢、症
状等により変化するので明確には特定することはできな
いが、ヒトに投与する場合、アデノシン類が、体重1Kg
および1日当り、一般に0. 01〜100.0mg、好ま
しくは0. 1〜10.0mg投与されるような量であり、
この量を1日1回又は2〜4回に分けて投与することが
好ましい。The external preparation of the present invention can be administered by transdermal administration which is directly applied or sprayed on the skin. Also,
The dose cannot be clearly specified because it varies depending on the specific mode of the external preparation, the age of the user, symptoms, etc., but when administered to humans, adenosines have a body weight of 1 kg.
And an amount that is generally 0.01 to 100.0 mg, preferably 0.1 to 10.0 mg per day,
This amount is preferably administered once a day or divided into 2 to 4 times.
【0019】本発明養毛料について 本発明外用剤の最も好適な態様として、養毛料が挙げら
れる(本発明養毛料)。 Regarding the hair restoration of the present invention, the most preferred embodiment of the external preparation of the invention is a hair restoration (the hair restoration of the present invention).
【0020】一般に、脱毛の原因としては、毛包や皮脂
腺等の器官における男性ホルモンの活性化、毛乳頭や毛
包への血流量の低下、皮脂の分泌過剰、過酸化物の生成
等による頭皮の異常、栄養不良等が考えられている。In general, the causes of hair loss include the activation of androgens in organs such as hair follicles and sebaceous glands, a decrease in blood flow to the dermal papilla and hair follicles, excessive secretion of sebum, generation of peroxide, and the like. Abnormality, malnutrition, etc. are considered.
【0021】このため、従来の養毛料には、これらの原
因を取り除いたり、又は、軽減する作用を持つ成分が一
般に配合されている。しかしながら、それにもかかわら
ず、従来の養毛料では、脱毛防止、発毛促進作用等の養
毛作用は必ずしも充分なものではなかった。これはおそ
らく、脱毛の原因が様々であり、また、発毛の機構も非
常に複雑であるためであると考えられている。このよう
な脱毛の原因の多様性や発毛の機構の複雑性を考慮すれ
ば、優れた養毛作用を有する新規養毛料の提供が望まれ
る。For this reason, conventional hair nourishes are generally compounded with components having an action of eliminating or reducing these causes. Nevertheless, nevertheless, conventional hair restorations have not always had sufficient hair restoration effects such as hair loss prevention and hair growth promotion. This is presumably due to various causes of hair loss and the very complex mechanism of hair growth. In view of the variety of causes of such hair loss and the complexity of the hair growth mechanism, it is desired to provide a new hair restorer having an excellent hair restorer action.
【0022】本発明養毛料は、アデノシン類を配合する
ことにより、その優れた血行促進効果により、頭皮にお
ける血行を促進させ、脱毛防止作用、発毛促進作用等を
発揮することができる。The hair restorer of the present invention, by blending adenosines, can promote blood circulation in the scalp due to its excellent blood circulation promoting effect, and can exhibit a hair loss preventing effect, a hair growth promoting effect, and the like.
【0023】本発明養毛料が採り得る剤型は、皮膚、特
に頭皮に適用可能な剤型であれば特に限定されず、例え
ば液状,乳液,軟膏等を選択可能である。また、本発明
養毛料の形態は任意であり、例えばトニック,ヘアーク
リーム,ムース,シャンプー,リンス等の形態を採るこ
とができる。The dosage form that can be taken by the hair restorer of the present invention is not particularly limited as long as it is a dosage form applicable to the skin, especially the scalp, and for example, liquid, emulsion, ointment and the like can be selected. Further, the form of the hair restorer of the present invention is arbitrary, and for example, a form such as a tonic, a hair cream, a mousse, a shampoo, and a rinse can be employed.
【0024】本発明養毛料には、前記の一般成分におい
て、特に、既存の養毛料に配合され得る公知の養毛成分
を積極的に配合することができる。例えば、抗菌剤とし
て、ヒノキチオール,ヘキサクロロフェン,ベンザルコ
ニウムクロリド,セチルピリジニウムクロリド,ウンデ
シレン酸,トリクロロカルバニリド,ビチオノール等を
配合することができる。In the hair growth composition of the present invention, among the above-mentioned general ingredients, in particular, known hair growth ingredients which can be blended with existing hair growth compositions can be positively blended. For example, as an antibacterial agent, hinokitiol, hexachlorophen, benzalkonium chloride, cetylpyridinium chloride, undecylenic acid, trichlorocarbanilide, bithionol and the like can be blended.
【0025】また、薬剤成分として、ニコチン酸アミ
ド,ニコチン酸ベンジル,ビタミンE又はその誘導体,
例えばビタミンEアセテート,センブリエキス,塩化カ
ルプロニウム,アセチルコリン誘導体等の血管拡張剤;
セファランチン等の皮膚機能亢進剤;グリチルレチン酸
又はその誘導体,紫根エキス等の消炎剤;エストラジオ
ール,エストロン等の女性ホルモン剤;セリン,メチオ
ニン,アルギニン等のアミノ酸類;ビタミンA,ビタミ
ンB1 ,ビタミンB6 ,ビオチン,パントテン酸又はそ
の誘導体等のビタミン類;アデニン,シトシン,チミ
ン,グアニン等の核酸等を配合することができる。Further, nicotinamide, benzyl nicotinate, vitamin E or a derivative thereof,
Vasodilators such as, for example, vitamin E acetate, assembly extract, carpronium chloride, acetylcholine derivatives;
Skin function enhancers such as cepharanthin; antiinflammatory agents such as glycyrrhetinic acid or a derivative thereof, purple root extract; female hormones such as estradiol and estrone; amino acids such as serine, methionine, and arginine; vitamin A, vitamin B 1 , and vitamin B 6 , Biotin, pantothenic acid or derivatives thereof, and nucleic acids such as adenine, cytosine, thymine, guanine and the like.
【0026】さらに、必要に応じて、サリチル酸,亜鉛
又はその誘導体,乳酸又はそのアルキルエステル等の薬
剤;メントール等の清涼剤;クエン酸等の有機酸類を配
合することができる。Further, if necessary, a drug such as salicylic acid, zinc or a derivative thereof, lactic acid or an alkyl ester thereof, a cooling agent such as menthol, and an organic acid such as citric acid can be added.
【0027】本発明養毛料は、ヒトを始めとする哺乳動
物において、優れた脱毛防止作用と共に、発毛促進作用
及び育毛作用を有し、ヘアーケアー用の医薬品,医薬部
外品又は化粧品として有用である。The hair restorer of the present invention has an excellent hair loss-promoting action, a hair growth-promoting action and a hair-growth action in mammals including humans, and is useful as a pharmaceutical, quasi-drug or cosmetic for hair care. It is.
【0028】[0028]
【実施例】以下、実施例により本発明をさらに具体的に
説明するが、これらの実施例により本発明の技術的範囲
が限定的に解釈されるべきものではない。なお、以下の
実施例等において「%」と表示され、かつ配合量を示す
ものは、、特に断らない限り、重量%を意味する。ま
ず、本発明外用剤の有効成分の血行促進作用を検討する
ために、血流増加試験を行った。EXAMPLES Hereinafter, the present invention will be described more specifically with reference to Examples, but it should be understood that the technical scope of the present invention is not limited to these Examples. In the following Examples and the like, "%" and the amount indicating the blending amount mean% by weight unless otherwise specified. First, a blood flow increase test was performed to examine the blood circulation promoting action of the active ingredient of the external preparation of the present invention.
【0029】1.血流増加試験 試験サンプルとして、0.75%アデノシン、0.
75%ニコチン酸アミド及びプラセボ製剤を調製し
た。また、被検者は、健常人パネル(20〜60歳の男
女16名)とした。1. Blood flow increase test As a test sample, 0.75% adenosine, 0.
A 75% nicotinamide and placebo formulation was prepared. The subjects were healthy panel (16 men and women aged 20 to 60 years).
【0030】パネルを、恒温・恒湿室(25℃)内で、
30分間安静させた。その後、手首に近い方から、5cm
以上の間隔を空けて、測定部位A,B,Cを定め、レー
ザードップラー計(OMEGA-FLOW FLO-N1)で、各部位の血
流量を事前測定した(0時間のデータに該当する)。The panel is placed in a constant temperature / humidity chamber (25 ° C.)
Rested for 30 minutes. Then, 5cm from the side near the wrist
At the above intervals, measurement sites A, B, and C were determined, and the blood flow at each site was measured in advance by a laser Doppler meter (OMEGA-FLOW FLO-N1) (corresponding to data at 0 hours).
【0031】なお、測定部位1か所に付き、プローブ及
び血流計を各1台準備した(本試験では、測定部位の数
に応じ、各3台を準備した)。上記の事前測定後、各試
験サンプルを、直径8mmの各測定部位A,B,Cに10
μL 塗布した。次いで、塗布1時間後までの、血流量
(V:ボルト)及び血流速度(V:ボルト)を、5分毎
にモニタリングし、各値を、パネル全員の平均値として
算出した。In addition, one probe and one blood flow meter were prepared for one measurement site (three devices were prepared according to the number of measurement sites in this test). After the above pre-measurement, each test sample was placed in each of the measurement sites A, B, and C having a diameter of 8 mm.
μL was applied. Next, the blood flow (V: volt) and blood flow velocity (V: volt) were monitored every 5 minutes until one hour after application, and each value was calculated as the average value of all the panels.
【0032】0時間における上記血流量に対する時間毎
の血流量の比(%)を、血行促進効果の指標として、各
試験サンプルの血行促進効果を評価した。結果を、第1
図に示す。The blood flow promoting effect of each test sample was evaluated using the ratio (%) of the blood flow per hour to the above blood flow at 0 hour as an index of the blood flow promoting effect. The result is the first
Shown in the figure.
【0033】第1図において、試験開始後30分以降
に、著しくパネルの血行が促進されたことが判明した。
この結果により、本発明に係わる有効成分のアデノシン
に優れた血行促進作用が認められることが判明した。In FIG. 1, it was found that the blood circulation of the panel was remarkably promoted 30 minutes after the start of the test.
From these results, it has been found that adenosine, an active ingredient according to the present invention, has an excellent blood circulation promoting action.
【0034】また、0.75%アデノシン5’−リン酸
についても、上記と同様の試験を行った。その結果、ア
デノシン5’−リン酸についても、著しい血行促進作用
が認められた。The same test as described above was conducted for 0.75% adenosine 5'-phosphate. As a result, a remarkable blood circulation promoting effect was also observed for adenosine 5'-phosphate.
【0035】よって、アデノシン、アデノシン5’−リ
ン酸及び/又はアデノシン5’−リン酸の塩を有効成分
とすることにより、優れた血行促進を発揮する剤が提供
されることが見出された。 2.養毛試験 次に、本発明外用剤の典型的かつ好適な態様である養毛
料としての有用性についての実施例を記載する。Thus, it has been found that an agent exhibiting excellent blood circulation promotion can be provided by using adenosine, adenosine 5'-phosphate and / or adenosine 5'-phosphate as an active ingredient. . 2. Hair Restoration Test Next, examples of usefulness as a hair restorative, which is a typical and preferred embodiment of the external preparation of the present invention, will be described.
【0036】まず、養毛試験等に用いる養毛試料(液体
養毛料)の処方等を記載する。 〔実施例1〕 液状養毛料の調製 配合成分 配合量(重量%) アデノシン 3.0 70%エタノール 90.0 硬化ヒマシ油エチレンオキシド(40モル)付加物 1. 0 イオン交換水 残 部 <製造方法>アデノシンを、70%エタノール,硬化ヒ
マシ油エチレンオキシド(40モル)付加物及びイオン
交換水の一部と混合撹拌して溶解させた。得られた溶液
に、さらに、残りのイオン交換水を添加し、再度混合撹
拌して、液状の養毛料1を得た。First, the formulation of a hair growth sample (liquid hair growth material) used in a hair growth test and the like will be described. [Example 1] Preparation of liquid hair nourishing compounding ingredients (% by weight) adenosine 3.0 70% ethanol 90.0 hydrogenated castor oil ethylene oxide (40 mol) adduct 1.0 ion-exchanged water balance <Production method> Adenosine was dissolved in 70% ethanol, hydrogenated castor oil ethylene oxide (40 mol) adduct and part of ion-exchanged water with stirring. The remaining ion-exchanged water was further added to the obtained solution, and mixed and stirred again to obtain a liquid hair restoration 1.
【0037】 〔実施例2〕 液状養毛料の調製 配合成分 配合量(重量%) アデノシン5’−リン酸 0.5 70%エタノール 90.0 オレイン酸ナトリウム 0. 01 ドデシルベンゼンスルホン酸 0. 4 硬化ヒマシ油エチレンオキシド(40モル)付加物 0. 5 イオン交換水 残 部 <製造方法>アデノシン5’−リン酸を、70%エタノ
ール,オレイン酸ナトリウム,ドデシルベンゼンスルホ
ン酸,硬化ヒマシ油エチレンオキシド(40モル)付加
物及びイオン交換水の一部と混合撹拌して溶解させた。
得られた溶液に、さらに、残りのイオン交換水を添加
し、再度混合撹拌して、液状の養毛料2を得た。[0037] Example 2 Preparation Ingredient amount of the liquid hair tonic (% by weight) adenosine 5'-phosphate 0.5 70% Ethanol 90.0 Sodium oleate 0.01 dodecylbenzenesulfonate 0.4 curing Castor oil ethylene oxide (40 mol) adduct 0.5 ion-exchanged water balance <Production method> 70% ethanol, sodium oleate, dodecylbenzenesulfonic acid, hydrogenated castor oil ethylene oxide (40 mol) The adduct and a part of ion-exchanged water were mixed and stirred to dissolve.
To the obtained solution, the remaining ion-exchanged water was further added and mixed and stirred again to obtain a liquid hair restorative 2.
【0038】 〔実施例3及び4〕 液状養毛料の調製 配合成分 配合量(重量%) アデノシン5’−リン酸2ナトリウム又は アデノシン5’−リン酸2カリウム 1.0 70%エタノール 90.0 セスキオレイン酸ソルビタン 0. 4 硬化ヒマシ油エチレンオキシド(40モル)付加物 0. 6 イオン交換水 残 部 <製造方法>アデノシン5’−リン酸2ナトリウム又は
アデノシン5’−リン酸2カリウムを、70%エタノー
ル,セスキオレイン酸ソルビタン,硬化ヒマシ油エチレ
ンオキシド(40モル)付加物及びイオン交換水の一部
と混合撹拌して溶解させた。得られた溶液に、さらに、
残りのイオン交換水を添加し撹拌して、液状の養毛料3
及び4を得た。Examples 3 and 4 Preparation of Liquid Hair Restoration Compounding Components (Weight%) Adenosine 5′-disodium phosphate or Adenosine 5′-dipotassium phosphate 1.0 70% Ethanol 90.0 Sesqui Sorbitan oleate 0.4 Hydrogenated castor oil ethylene oxide (40 mol) adduct 0.6 Ion-exchanged water Remaining <Production method> Adenosine 5'-disodium phosphate or adenosine 5'-dipotassium phosphate was treated with 70% ethanol , Sorbitan sesquioleate, hydrogenated castor oil, ethylene oxide (40 mol) adduct, and a portion of ion-exchanged water were mixed and dissolved by stirring. In the resulting solution,
Add the remaining ion-exchanged water and stir to obtain a liquid hair restoration 3
And 4 were obtained.
【0039】 〔実施例5〕 液状養毛料の調製 配合成分 配合量(重量%) アデノシン5’−リン酸ナトリウム二水和物 0. 3 70%エタノール 90.0 ラウロイルタウリン 0. 1 塩化セチルピリジウム 0. 01 硬化ヒマシ油エチレンオキシド(40モル)付加物 0. 89 イオン交換水 残 部 <製造方法>アデノシン5’−リン酸ナトリウム二水和
物を、70%エタノール,ラウロイルタウリン,塩化セ
チルピリジウム,硬化ヒマシ油エチレンオキシド(40
モル)付加物及びイオン交換水の一部に混合撹拌して溶
解させた。得られた溶液に、さらに、残りのイオン交換
水を添加し混合して、液状の養毛料5を得た。Example 5 Preparation of Liquid Hair Restoration Ingredients Ingredients (% by weight) Adenosine 5'-sodium phosphate dihydrate 0.3 70% ethanol 90.0 Lauroyltaurine 0.1 Cetylpyridinium chloride 0.01 hydrogenated castor oil ethylene oxide (40 mol) adduct 0.89 ion-exchanged water balance <Production method> Adenosine 5'-sodium phosphate dihydrate was treated with 70% ethanol, lauroyl taurine, cetyl pyridium chloride, Hydrogenated castor oil ethylene oxide (40
Mol) The adduct and a part of ion-exchanged water were mixed and dissolved by stirring. To the resulting solution, the remaining ion-exchanged water was further added and mixed to obtain a liquid hair restorative 5.
【0040】次に、上記実施例1〜5で得られた養毛料
1〜5について、発毛促進作用を調べた。また、養毛料
1及び3について、養毛作用を調べた。発毛促進作用試験 実験動物として、毛周期の休止期にあるC3H/HeN
CrJマウスを使用し、小川らの方法(ノーマル・アン
ド・アブノーマル・エピダーマル・ディファレンシエー
ション(Normal and Abnormal Epidermal Differentiati
on), M. Seiji及びI.A. Bernstein編集,第159〜1
70頁,1982年,東大出版)により行った。Next, the hair growth-promoting effects of the hair nourishes 1 to 5 obtained in Examples 1 to 5 were examined. In addition, hair growth effects of hair growth agents 1 and 3 were examined. As a test animal for hair growth promoting action test , C3H / HeN
Using CrJ mice, the method of Ogawa et al. (Normal and Abnormal Epidermal Differentiati
on), edited by M. Seiji and IA Bernstein, 159-1
70, 1982, The University of Tokyo Press).
【0041】すなわち、マウスを1群10匹として6群
用意し、バリカン及びシェーバーでマウスの背部を剃毛
した後、それぞれの群に対して、被検試料(養毛料1〜
5)又は対照試料(70%エタノール溶液)を1日1
回、0.1mLずつ、剃毛した背部に塗布した。25日後
に毛の再生面積を測定した。That is, six groups of 10 mice were prepared, and the backs of the mice were shaved with a hair clipper and a shaver.
5) Or a control sample (70% ethanol solution)
Each time, 0.1 mL was applied to the shaved back. After 25 days, the regenerated area of the hair was measured.
【0042】結果を第1表に示す(数値は平均値であ
る)。 第1表 ──────────────────────────────────── 試料 毛再生面積(%) 試料 毛再生面積(%) ──────────────────────────────────── 養毛料1 96 養毛料2 65 養毛料3 75 養毛料4 55 養毛料5 45 対 照 2.0 ──────────────────────────────────── 第1表より明らかなように、本発明養毛料は、マウスの
発毛促進作用試験において有意な効果を示し、本発明養
毛料が、優れた発毛促進作用を有することが判った。The results are shown in Table 1 (the numerical values are average values). Table 1 試 料 Sample Hair Regeneration Area (%) Sample Hair Regeneration Area (%) 毛 Hair restoration 1 96 Hair restoration 2 65 Hair restoration 3 75 Hair restorer 4 55 Hair restorer 5 45 Reference 2.0 ──────────────────────────────────── As is clear from Table 1, the hair restoration of the present invention showed a significant effect in a test for promoting hair growth in mice, and it was found that the hair restoration of the present invention had an excellent hair growth promoting action.
【0043】養毛作用試験 本発明養毛料の脱毛防止作用,発毛促進作用等の養毛作
用を調べるために、ヒトに対して、以下の方法でトリコ
グラム試験を実施した。被験試料は、上記発毛試験に用
いた養毛料1及び3であり、対照試料は、70%エタノ
ールである。 Test for Hair Restoration In order to examine the hair restoring effects of the hair restorer of the present invention, such as the hair loss preventing effect and the hair growth promoting effect, a tricogram test was performed on humans by the following method. The test samples are hair restorations 1 and 3 used in the above hair growth test, and the control sample is 70% ethanol.
【0044】すなわち、養毛料1及び3並びに対照とし
て70%エタノールを、それぞれ男性被験者100名の
頭皮に1日2回,1回2mLずつ6か月間連続して塗布し
た。塗布直前及び6か月間塗布終了直後に被験者1名に
つき100本ずつ毛髪を抜去し、抜去毛髪の毛根を顕微
鏡下で観察し、毛根の形態から休止期毛根数を計数し、
休止期毛根の割合を求めた。That is, hair growth products 1 and 3 and 70% ethanol as a control were applied to the scalp of 100 male subjects twice a day, 2 mL at a time, continuously for 6 months. Immediately before application and immediately after completion of application for 6 months, 100 hairs were removed from each test subject, the roots of the removed hairs were observed under a microscope, and the number of telogen hair roots was counted from the form of the hair roots.
The proportion of telogen roots was determined.
【0045】休止期毛根の割合の増減により、被験試料
(養毛料1,3)及び対照試料(70%エタノール)の
養毛作用を比較した。休止期毛根とは成長の止まった毛
の毛根であり、脱毛を訴えるヒトは、正常なヒトよりも
この休止期毛根の割合が多いことが認められている。The hair growth effects of the test sample (hair growth products 1, 3) and the control sample (70% ethanol) were compared by increasing or decreasing the ratio of the telogen roots. The telogen follicles are hair follicles that have stopped growing, and it has been recognized that humans who complain of hair loss have a higher percentage of these telogen follicles than normal humans.
【0046】また、養毛作用の評価は、次の基準で判定
した。 <判定基準> 有効:休止期毛根の割合が20%以上減少した被験者が
40%以上である場合 やや有効:休止期毛根の割合が20%以上減少した被験
者が20%以上である場合 無効:休止期毛根の割合が20%以上減少した被験者が
20%未満である場合結果を第2表に示す。The evaluation of the hair-growing action was determined according to the following criteria. <Judgment criteria> Effective: When the proportion of the telogen hair root decreased by 20% or more is 40% or more Slightly effective: When the proportion of the telogen hair root decreased by 20% or more is 20% or more Invalid: Pause The results are shown in Table 2 in the case where the proportion of the hair follicles decreased by 20% or more was less than 20%.
【0047】 第2表 ──────────────────────────────────── 被験者の割合(%) ─────────────────────────養毛作用の 試料 休止期毛根の割合が 評価 20%以上減少 20%未満減少 20%以上増加 〜20%未満増加 ──────────────────────────────────── 養毛料1 42 33 25 有効 養毛料3 35 30 35 やや有効 対 照 10 50 40 無効 ──────────────────────────────────── この第2表の結果から、アデノシン又はアデノシン5’
−リン酸の塩を含む本発明養毛料について、ヒトのトリ
コグラム試験において、有意な養毛作用が認められるこ
とが明らかとなった。Table 2 割 合 Ratio of test subjects (%) ──毛 Sample of hair-growing action Evaluation of the ratio of hair roots in the telogen phase decreased by 20% or more Reduced by less than 20% Increased by 20% or more 2020% Less than increase 毛 Hair restoration 1 42 33 25 Effective hair restoration 3 35 30 35 Somewhat effective Reference 10 50 40 Invalid のFrom the results, adenosine or adenosine 5 ′
-It was revealed that a hair growth effect of the present invention containing a phosphoric acid salt was found to be significant in a human trichogram test.
【0048】また、アデノシン5’−リン酸を含む本発
明養毛料(養毛料2)についても、発毛促進作用が認め
られたことから、アデノシン5’−リン酸を含む本発明
養毛料についても、同様の養毛作用が認められることが
明らかである。Also, the hair restoration of the present invention containing adenosine 5'-phosphate (hair restoration 2) was confirmed to have a hair growth promoting effect. It is clear that the same hair-growing action is observed.
【0049】実施例1〜5に加え、本発明に従う別の態
様の養毛料の処方を、さらに実施例として示す。以下の
実施例で得られた養毛料の全てについて、上記液状養毛
料1〜5とほぼ同様の発毛促進作用及び養毛作用が認め
れた。In addition to Examples 1 to 5, the formulation of another embodiment of a hair restorer according to the present invention is further illustrated as an example. In all of the hair restorations obtained in the following examples, hair growth promoting action and hair restoration action almost similar to those of the liquid hair restorations 1 to 5 were observed.
【0050】また、後述の実施例9以降に、本発明外用
剤の養毛料以外の態様の処方例を示す。これらの処方の
実施例についても、上記の血流増加試験を行ったとこ
ろ、被検者の皮膚近傍の血行が明らかに促進した。In addition, Examples 9 and later, which will be described later, show examples of formulations of the external preparation of the present invention other than the hair restorer. The blood flow increase test described above was also performed on the examples of these formulations, and the blood circulation near the skin of the subject was clearly promoted.
【0051】 〔実施例6〕 乳液型養毛料の調製 配合成分 配合量(重量%) (A相) アデノシン5’−リン酸2ナトリウム 1. 0 硬化ヒマシ油エチレンオキシド(60モル)付加物 2. 0 グリセリン 10. 0 ジプロピレングリコール 10. 0 1, 3−ブチレングリコール 5. 0 ポリエチレングリコール1500 5. 0 (B相) セチルイソオクタネート 10. 0 スクワラン 5. 0 ワセリン 2. 0 プロピルパラベン 2. 0 (C相) カルボキシビニルポリマー1%水溶液 30. 0 ヘキサメタリン酸ソーダ 0. 03 イオン交換水 8. 35 (D相) イオン交換水 4. 5 (E相) 水酸化カリウム 0. 12 イオン交換水 5. 0 <製造方法>A相、B相をそれぞれ60℃で加熱溶解
し、混合してホモミキサー処理してゲルを作った。これ
にD相を徐々に添加しホモミキサーで分散させた。Example 6 Preparation of Emulsion-Type Hair Restoration Compounding Components (Weight%) (A phase) Adenosine 5′-disodium phosphate 1.0 Hardened castor oil ethylene oxide (60 mol) adduct 2.0 Glycerin 10.0 Dipropylene glycol 10.0 1,3-butylene glycol 5.0 Polyethylene glycol 1500 5.0 (Phase B) Cetyl isooctanoate 10.0 Squalane 5.0 Vaseline 2.0 Propylparaben 2.0 ( C phase) 1% aqueous solution of carboxyvinyl polymer 30.0 Sodium hexametaphosphate 0.03 Ion exchange water 8.35 (D phase) Ion exchange water 4.5 (E phase) Potassium hydroxide 0.12 Ion exchange water 5.0 <Production method> A phase and B phase were each heated and dissolved at 60 ° C, mixed, and homomixed to form a gel. Phase D was gradually added thereto and dispersed with a homomixer.
【0052】次にこれに、溶解したC相を加え、最後に
溶解したE相を添加しホモミキサーで乳化してO/W乳
液型の養毛料を得た。 〔実施例7〕 クリーム状養毛料の調製 配合成分 配合量(重量%) (A相) 流動パラフイン 5. 0 セトステアリルアルコール 5. 5 グリセリルモノステアレート 3. 0 EO(20モル)−2−オクチルドデシルエーテル 3. 0 プロピルパラベン 0. 3 香料 0. 1 (B相) アデノシン 5. 0 グリセリン 8. 0 ジプロピレングリコール 20. 0 ポリエチレングリコール4000 5. 0 ドデシル硫酸ナトリウム 0. 1 ヘキサメタリン酸ソーダ 0. 005 イオン交換水 残 部 <製造方法>A相、B相をそれぞれ加熱溶解して混合
し、ホモミキサーで乳化してクリーム状の養毛料を得
た。Next, the dissolved C phase was added thereto, and finally the dissolved E phase was added and emulsified with a homomixer to obtain an O / W emulsion type hair restorer. [Example 7] Preparation of creamy hair restorer Component blending amount (% by weight) (A phase) Liquid paraffin 5.0 cetostearyl alcohol 5.5 glyceryl monostearate 3.0 EO (20 mol) -2-octyl Dodecyl ether 3.0 Propylparaben 0.3 Fragrance 0.1 (Phase B) Adenosine 5.0 Glycerin 8.0 Dipropylene glycol 20.0 Polyethylene glycol 4000 5.0 Sodium dodecyl sulfate 0.1 Sodium hexametaphosphate 0.005 Ion-exchanged water balance <Production method> A phase and B phase were each heated and dissolved, mixed, and emulsified with a homomixer to obtain a creamy hair restorer.
【0053】 〔実施例8〕 液状養毛料の調製 配合成分 配合量(重量%) アデノシン5’−リン酸カリウム 0. 5 ステアリルジメチルアミンオキシド 0. 5 硬化ヒマシ油エチレンオキシド(40モル)付加物 1. 0 95%エタノール 54. 0 イオン交換水 残 部 <製造方法>95%エタノールにイオン交換水を加え、
これに硬化ヒマシ油エチレンオキシド(40モル)付加
物及びステアリルジメチルアミンオキシドを加えた後、
アデノシン5’−リン酸カリウムを加え、撹拌溶解し
て、液状の養毛料を得た。Example 8 Preparation of Liquid Hair Restoration Compounding Components (% by weight) Adenosine 5′-potassium phosphate 0.5 Stearyl dimethylamine oxide 0.5 Hardened castor oil ethylene oxide (40 mol) adduct 1. 0 95% ethanol 54.0 Ion-exchanged water balance <Production method> Ion-exchanged water was added to 95% ethanol,
After adding hydrogenated castor oil ethylene oxide (40 mol) adduct and stearyl dimethylamine oxide to this,
Adenosine 5'-potassium phosphate was added, and the mixture was stirred and dissolved to obtain a liquid hair restoration.
【0054】 〔実施例9〕 液状養毛料の調製 配合成分 配合量(重量%) N−ヤシラウリル−β−アミノプロピオン酸ソーダ 0. 2 アデノシン5’−リン酸2ナトリウム水和物 1. 0 ドデシルベンゼンスルホン酸ナトリウム 0. 5 硬化ヒマシ油エチレンオキシド(40モル)付加物 1. 0 95%エタノール 54. 0 イオン交換水 残 部 <製造方法>95%エタノールにイオン交換水を加え、
これに硬化ヒマシ油エチレンオキシド(40モル)付加
物,ドデシルベンゼンスルホン酸ナトリウム及びN−ヤ
シラウリル−β−アミノプロピオン酸ソーダを加えた
後、アデノシン5’−リン酸2ナトリウム水和物を加
え、撹拌溶解して、液状の養毛料を得た。Example 9 Preparation of Liquid Hair Restoration Ingredients Incorporation Amount (% by weight) N-cocolauryl-β-aminopropionate sodium 0.2 adenosine 5′-disodium phosphate hydrate 1.0 dodecylbenzene Sodium sulfonate 0.5 hydrogenated castor oil ethylene oxide (40 mol) adduct 1.0 95% ethanol 54.0 ion-exchanged water balance <Production method> Add ion-exchanged water to 95% ethanol,
After addition of hydrogenated castor oil ethylene oxide (40 mol) adduct, sodium dodecylbenzenesulfonate and sodium N-cocolauryl-β-aminopropionate, adenosine 5′-disodium phosphate hydrate was added, followed by stirring and dissolution. Thus, a liquid hair restoration was obtained.
【0055】 〔実施例10〕 クリームの調製 配合成分 配合量(重量%) ステアリン酸 5.0 ステアリルアルコール 4.0 イソプロピルミリステート 18.0 グリセリンモノステアリン酸エステル 3.0 プロピレングリコール 10.0 アデノシン 3.0 水酸化カリウム 0.2 亜硫酸水素ナトリウム 0.01 防腐剤 適 量 香料 適 量 イオン交換水 残 部 <製造方法>イオン交換水に、プロピレングリコールと
アデノシンと水酸化カリウムを加え、加熱して70℃に
保った(水相)。他の成分を混合融解して、70℃に保
った(油相)。水相を、油相に徐々に加え、全部加え終
わってから、しばらく、その温度に保ち、反応を起こさ
せた。その後、ホモミキサーで均一に乳化し、よくかき
まぜながら、30℃まで冷却して、クリームを得た。Example 10 Preparation of Cream Ingredients Components (Weight%) Stearic Acid 5.0 Stearyl Alcohol 4.0 Isopropyl Myristate 18.0 Glycerin Monostearate 3.0 Propylene Glycol 10.0 Adenosine 3 0.0 Potassium hydroxide 0.2 Sodium bisulfite 0.01 Preservatives Appropriate amount Fragrance Appropriate amount Ion-exchanged water balance <Production method> Add propylene glycol, adenosine and potassium hydroxide to ion-exchanged water and heat to 70%. C. (aqueous phase). The other components were mixed and melted and kept at 70 ° C. (oil phase). The water phase was gradually added to the oil phase, and after the addition was completed, the temperature was maintained for a while to cause a reaction. Thereafter, the mixture was uniformly emulsified with a homomixer and cooled to 30 ° C. while stirring well to obtain a cream.
【0056】 〔実施例11〕 クリームの調製 配合成分 配合量(重量%) ステアリン酸 2.0 ステアリルアルコール 7.0 水添ラノリン 2.0 スクワラン 5.0 2−オクチルドデシルアルコール 3.0 ポリオキシエチレン(25モル) セチルアルコールエーテル 3.0 グリセリンモノステアリン酸エステル 2.0 プロピレングリコール 5.0 アデノシン5’−リン酸 0.75 亜硫酸水素ナトリウム 0.03 エチルパラベン 0.3 香料 適 量 イオン交換水 残 余 <製造方法>イオン交換水にプロピレングリコールを加
え、加熱して70℃に保った(水相)。他の成分を混合
し、加熱融解して、70℃に保った(油相)。水相に油
相を加え、予備乳化を行い、ホモミキサーで均一に乳化
した後、よくかきまぜながら、30℃まで冷却して、ク
リームを得た。Example 11 Preparation of Cream Blending Components (% by Weight) Stearic Acid 2.0 Stearyl Alcohol 7.0 Hydrogenated Lanolin 2.0 Squalane 5.0 2-Octyldodecyl Alcohol 3.0 Polyoxyethylene (25 mol) Cetyl alcohol ether 3.0 Glycerin monostearate 2.0 Propylene glycol 5.0 Adenosine 5'-phosphate 0.75 Sodium bisulfite 0.03 Ethyl paraben 0.3 Perfume Appropriate amount Ion-exchanged water residue <Production method> Propylene glycol was added to ion-exchanged water, and heated to 70 ° C (aqueous phase). The other components were mixed, melted by heating, and kept at 70 ° C. (oil phase). The oil phase was added to the water phase, preliminarily emulsified, uniformly emulsified by a homomixer, and then cooled to 30 ° C. while stirring well to obtain a cream.
【0057】 〔実施例12〕 乳液の調製 配合成分 配合量(重量%) ステアリン酸 2.5 セチルアルコール 1.5 ワセリン 5.0 流動パラフィン 10.0 ポリオキシエチレン(10モル) モノオレイン酸エステル 2.0 ポリエチレングリコール1500 3.0 アデノシン 0.75 トリエタノールアミン 1.0 カルボキシビニルポリマー 0.05 アデノシン5’−リン酸 0.02 亜硫酸水素ナトリウム 0.01 エチルパラベン 0.3 香料 適 量 イオン交換水 残 部 <製造方法>少量のイオン交換水にプロピレングリコー
ルを加え、これを加熱して70℃に保った(水相)。他
の成分を混合し、加熱融解して、70℃に保った(油
相)。油相をかきまぜながら、これに水相を徐々に加
え、ホモミキサーで均一に乳化した。乳化後、よくかき
まぜながら30℃まで冷却して、乳液を得た。Example 12 Preparation of Emulsion Compounding Components (% by weight) Stearic Acid 2.5 Cetyl Alcohol 1.5 Vaseline 5.0 Liquid Paraffin 10.0 Polyoxyethylene (10 mol) Monooleate 2 0.0 Polyethylene glycol 1500 3.0 Adenosine 0.75 Triethanolamine 1.0 Carboxyvinyl polymer 0.05 Adenosine 5'-phosphate 0.02 Sodium bisulfite 0.01 Ethylparaben 0.3 Perfume Appropriate amount Ion-exchanged water Residue <Production method> Propylene glycol was added to a small amount of ion-exchanged water, and this was heated and maintained at 70 ° C (aqueous phase). The other components were mixed, melted by heating, and kept at 70 ° C. (oil phase). While stirring the oil phase, the aqueous phase was gradually added thereto, and the mixture was uniformly emulsified with a homomixer. After emulsification, the mixture was cooled to 30 ° C. while stirring well to obtain an emulsion.
【0058】 〔実施例13〕 乳液の調製 配合成分 配合量(重量%) マイクロクリスタリンワックス 1.0 ミツロウ 2.0 ラノリン 20.0 流動パラフィン 10.0 スクワラン 5.0 ソルビタンセスキオレイン酸エステル 4.0 ポリオキシエチレン(20モル) ソルビタンセスキオレイン酸エステル 1.0 プロピレングリコール 7.0 アデノシン−5’リン酸2ナトリウム又は アデノシン−5’リン酸2カリウム 5.0 亜硫酸水素ナトリウム 0.01 エチルパラベン 0.3 香料 適 量 イオン交換水 残 部 <製造方法>イオン交換水に、プロピレングリコールを
加え、加熱して70℃に保った(水相)。他の成分を混
合し、加熱融解して70℃に保った(油相)。油相をか
きまぜながら、これに水相を徐々に加え、ホモミキサー
で均一に乳化した。乳化後、よくかきまぜながら30℃
まで冷却して、乳液を得た。Example 13 Preparation of Emulsion Formulation Components (% by weight) Microcrystalline wax 1.0 Beeswax 2.0 Lanolin 20.0 Liquid paraffin 10.0 Squalane 5.0 Sorbitan sesquioleate 4.0 Polyoxyethylene (20 mol) Sorbitan sesquioleate 1.0 Propylene glycol 7.0 Disodium adenosine-5 'phosphate or dipotassium adenosine-5' phosphate 5.0 Sodium bisulfite 0.01 Ethyl paraben 0.0 3 Appropriate amount of perfume Ion-exchanged water balance <Production method> Propylene glycol was added to ion-exchanged water, and heated to 70 ° C (aqueous phase). The other components were mixed, melted by heating and kept at 70 ° C. (oil phase). While stirring the oil phase, the aqueous phase was gradually added thereto, and the mixture was uniformly emulsified with a homomixer. After emulsification, 30 ° C with good stirring
Cooled to give an emulsion.
【0059】 〔実施例14〕 美容液の調製 配合成分 配合量(重量%) (A相) エチルアルコール(95%) 10.0 ポリオキシエチレン(20モル)オクチルドデカノール 1.0 パントテニルエチルエーテル 0.1 アデノシン 2.0 メチルパラベン 0.15 (B相) 水酸化カリウム 0.1 (C相) グリセリン 5.0 ジプロピレングリコール 10.0 亜硫酸水素ナトリウム 0.03 カルボキシビニルポリマー 0.2 イオン交換水 残 部 <製造方法>A相、C相を、それぞれ均一に溶解し、C
相にA相を加えて可溶化した。次いで、これにB相を添
加して、美容液を得た。[0059] Example 14 Preparation Ingredient of serums (wt%) (A phase) Ethyl alcohol (95%) 10.0 Polyoxyethylene (20 moles) octyldodecanol 1.0 Pantothenyl ethyl ether 0.1 Adenosine 2.0 Methyl paraben 0.15 (B phase) Potassium hydroxide 0.1 (C phase) Glycerin 5.0 Dipropylene glycol 10.0 Sodium bisulfite 0.03 Carboxyvinyl polymer 0.2 Ion exchange water Remaining part <Production method> A phase and C phase are each dissolved uniformly,
Phase A was added to solubilize. Next, the phase B was added thereto to obtain a serum.
【0060】[0060]
【発明の効果】本発明によれば、ヒトを始めとする哺乳
動物の皮膚近傍において優れた血行促進効果を発揮す
る、血行促進外用剤が提供され、さらに、脱毛防止作用
及び発毛促進作用等の優れた養毛作用を有する養毛料も
提供される。According to the present invention, there is provided an external preparation for promoting blood circulation, which exhibits an excellent blood circulation promoting effect near the skin of mammals such as humans, and further has an effect of preventing hair loss and promoting hair growth. A hair restorer having an excellent hair restorer action is also provided.
【図1】血流促進試験の結果を示す図面である。FIG. 1 is a drawing showing the results of a blood flow promotion test.
Claims (2)
/又はアデノシン5’−リン酸の塩を有効成分として含
有する血行促進外用剤。An external preparation for promoting blood circulation containing adenosine, adenosine 5'-phosphate and / or adenosine 5'-phosphate as an active ingredient.
血行促進外用剤。2. The external preparation for promoting blood circulation according to claim 1, wherein the preparation is in the form of a hair nourishing agent.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP29855999A JP3798927B2 (en) | 1998-10-26 | 1999-10-20 | Blood circulation promoting topical skin preparation |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10-321287 | 1998-10-26 | ||
JP32128798 | 1998-10-26 | ||
JP29855999A JP3798927B2 (en) | 1998-10-26 | 1999-10-20 | Blood circulation promoting topical skin preparation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004040003A Division JP3957690B2 (en) | 1998-10-26 | 2004-02-17 | Hair nourishing |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2000198718A true JP2000198718A (en) | 2000-07-18 |
JP2000198718A5 JP2000198718A5 (en) | 2005-01-13 |
JP3798927B2 JP3798927B2 (en) | 2006-07-19 |
Family
ID=26561571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP29855999A Expired - Fee Related JP3798927B2 (en) | 1998-10-26 | 1999-10-20 | Blood circulation promoting topical skin preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3798927B2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100616342B1 (en) * | 1998-10-26 | 2006-08-29 | 가부시키가이샤 시세이도 | Hair tonic composition |
JPWO2005044205A1 (en) * | 2003-11-11 | 2007-05-17 | 株式会社資生堂 | Method and composition for thickening hair |
WO2012057336A1 (en) * | 2010-10-29 | 2012-05-03 | ヤマサ醤油株式会社 | Hair growth agent composition |
JP2012201665A (en) * | 2011-03-28 | 2012-10-22 | Yamasa Shoyu Co Ltd | Skin care preparation having moisturing action |
JP2018058793A (en) * | 2016-10-05 | 2018-04-12 | 株式会社ディーエイチシー | Hair restorer composition and vascular endothelial growth factor production promoter |
JP2018534268A (en) * | 2015-09-30 | 2018-11-22 | アモーレパシフィック コーポレーションAmorepacific Corporation | Hair growth and / or hair growth promoting composition containing soyasaponin |
-
1999
- 1999-10-20 JP JP29855999A patent/JP3798927B2/en not_active Expired - Fee Related
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100616342B1 (en) * | 1998-10-26 | 2006-08-29 | 가부시키가이샤 시세이도 | Hair tonic composition |
JPWO2005044205A1 (en) * | 2003-11-11 | 2007-05-17 | 株式会社資生堂 | Method and composition for thickening hair |
WO2012057336A1 (en) * | 2010-10-29 | 2012-05-03 | ヤマサ醤油株式会社 | Hair growth agent composition |
JP2012201665A (en) * | 2011-03-28 | 2012-10-22 | Yamasa Shoyu Co Ltd | Skin care preparation having moisturing action |
JP2018534268A (en) * | 2015-09-30 | 2018-11-22 | アモーレパシフィック コーポレーションAmorepacific Corporation | Hair growth and / or hair growth promoting composition containing soyasaponin |
JP2018058793A (en) * | 2016-10-05 | 2018-04-12 | 株式会社ディーエイチシー | Hair restorer composition and vascular endothelial growth factor production promoter |
Also Published As
Publication number | Publication date |
---|---|
JP3798927B2 (en) | 2006-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3049593B2 (en) | Hair restorer | |
KR100616342B1 (en) | Hair tonic composition | |
JP2000198718A (en) | External preparation for promoting blood circulation | |
US20070116658A1 (en) | Hair tonic composition | |
JP2001288048A (en) | Composition for scalp and hair | |
JP2709513B2 (en) | Hair restoration | |
JP3957690B2 (en) | Hair nourishing | |
JP2001288046A (en) | Composition for scalp and hair | |
JP2001288045A (en) | Composition for scalp and hair | |
JP2000198718A5 (en) | ||
JPH10279437A (en) | Hair cosmetic | |
JPH07267830A (en) | Hair-growing hair-tonic agent | |
JPH11302131A (en) | Cosmetic for scalp and hair | |
JPH0640858A (en) | Hair tonic | |
JPH07149614A (en) | Hair tonic agent | |
JP3496896B2 (en) | Hair restorer and hair cosmetic | |
JPH10316575A (en) | Epidermis keratinization-promoting agent | |
JP2787451B2 (en) | Hair restoration | |
JPH1179937A (en) | Skin lotion for pimple treatment | |
JP3624318B2 (en) | Hair nourishing agent | |
JP2001288042A (en) | Composition for scalp and hair | |
JP2001122739A (en) | Hair tonic | |
JPH0782117A (en) | Hair tonic | |
JPH0352806A (en) | Hair-raising agent | |
JP2961528B2 (en) | Hair restoration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040217 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040217 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20041216 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051004 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051205 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20051206 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060131 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060306 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060404 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060421 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 3798927 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090428 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100428 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100428 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110428 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130428 Year of fee payment: 7 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140428 Year of fee payment: 8 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |